硫唑嘌呤与吗替麦考酚酯治疗重症肌无力的比较有效性(PROMISE-MG):一项前瞻性队列研究
在加拿大和美国19个学术中心开展前瞻性队列研究,纳入78例未接受过免疫抑制治疗的自身免疫性重症肌无力患者,比较硫唑嘌呤与吗替麦考酚酯的有效性。两组MG-QOL15r评分平均变化及临床复合结局均无显著差异,硫唑嘌呤相关不良事件可能更严重,作者认为需更多比较有效性研究来指导治疗选择。
要点
- 吗替麦考酚酯组与硫唑嘌呤组MG-QOL15r平均变化差异无统计学意义。
- 两组达到MG-QOL15r临床意义改善的比例差异未达统计学显著。
- 硫唑嘌呤相关不良事件可能更严重,但吗替麦考酚酯有致畸性。
核心结论
- 超过半数接受硫唑嘌呤或吗替麦考酚酯治疗的患者感觉生活质量改善,两药临床结局无差异。
- 硫唑嘌呤相关不良事件可能比吗替麦考酚酯更严重,尽管吗替麦考酚酯有致畸性。
- 低于推荐剂量的硫唑嘌呤可能有效,且剂量依赖性不良事件减少。
- 作者认为需要更多比较有效性研究来指导重症肌无力的治疗选择。
研究设计与样本
- 在加拿大和美国19个学术中心开展的前瞻性队列研究。
- 纳入年龄≥18岁、从未接受免疫抑制治疗的自身免疫性重症肌无力患者。
- 治疗医生决定药物选择、剂量、随访间隔和药物监测。
- 共167例患者入组,85例未接受硫唑嘌呤或吗替麦考酚酯被排除,4例因治疗开始时结局评分为0被排除,最终78例纳入分析。
- 采用倾向评分加权和广义线性回归模型。
主要发现
- 吗替麦考酚酯组47例(中位随访25个月,IQR 13.5-31.5),硫唑嘌呤组31例(中位随访20个月,IQR 13-30)。
- MG-QOL15r平均变化:吗替麦考酚酯组-10.4(95%CI -18.9至-1.3),硫唑嘌呤组-6.8(95%CI -17.2至3.6),平均差-3.3(95%CI -7.7至1.2;p=0.15)。
- MG-QOL15r临床意义改善:吗替麦考酚酯组38/47(81%),硫唑嘌呤组18/31(57%),风险差24.0%(95%CI -0.2至48.0;p=0.052)。
- 临床复合结局:吗替麦考酚酯组22/47(47.7%),硫唑嘌呤组9/31(28.1%),风险差19.6%(95%CI -4.9至44.2;p=0.12)。
- 不良事件:硫唑嘌呤组11/34(32%),吗替麦考酚酯组9/48(19%);最常见为硫唑嘌呤相关肝毒性5/34(15%)和吗替麦考酚酯相关胃肠道紊乱7/48(15%);无研究相关死亡。
关键数值与推荐
- MG-QOL15r临床意义改善定义为评分下降5分。
- 临床复合结局定义为疾病改善(美国重症肌无力基金会干预后状态为微小表现或更好)且不良事件负担低(常见不良事件术语标准≤1级)。
- 充分剂量和疗程:硫唑嘌呤≥2 mg/kg/天至少12个月,或吗替麦考酚酯≥2 g/天至少8个月。
- 描述性分析未发现充分剂量和疗程组与较低剂量或较短疗程组之间MG-QOL15r临床意义改善比例存在差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要更多比较有效性研究来指导重症肌无力的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myasthenia gravis is an autoimmune disorder of the neuromuscular junction. Treatment typically includes symptomatic oral cholinesterase inhibitors, immunosuppression, and immunomodulation. In addition to corticosteroids, azathioprine and mycophenolate mofetil are the most frequently used immunosuppressants in North America. We aimed to evaluate the comparative effectiveness of these two drugs, and to assess the effect of the dose and duration of treatment. METHODS: We did a prospective cohort study at 19 academic centres in Canada and the USA. We included patients (aged ≥18 years) with autoimmune myasthenia gravis, who were never treated with immunosuppressants. Treating clinicians determined the choice of medication, dose, follow-up intervals, and drug monitoring. Outcome measures and adverse events were recorded at each visit. We assessed two co-primary outcomes. The first was the patient-reported Myasthenia Gravis-Quality of Life 15-revised (MGQOL-15r) score, measured as the mean change from treatment initiation to the follow-up visit with the lowest score. A clinically meaningful reduction (CMR) in MGQOL-15r was defined as a 5-point decrease. The second was a composite clinical outcome of disease improvement (Myasthenia Gravis Foundation of America Post-Intervention Status Minimal Manifestations or better) and low adverse event burden (defined as grade ≤1 Common Terminology Criteria for Adverse Events). We also compared these outcomes in patients receiving an adequate dose and duration of azathioprine (≥2 mg/kg per day for at least 12 months) or mycophenolate mofetil (≥2 g per day for at least 8 months) and a lower dose or shorter duration of these agents. We used propensity score weighting with generalised linear regression models. This study is registered with ClinicalTrials.gov (NCT03490539). FINDINGS: Between May 1, 2018, and Aug 31, 2020, 167 patients were enrolled; 85 did not receive azathioprine or mycophenolate mofetil and were excluded. Four were excluded from outcome analyses because they had scores of 0 on an outcome measure at treatment initiation. Of the 78 patients included in analyses, 47 received mycophenolate mofetil (median follow-up 25 months [IQR 13·5-31·5]) and 31 received azathioprine (median follow-up 20 months [IQR 13-30]). The mean change in MG-QOL15r was -10·4 (95% CI -18·9 to -1·3) with mycophenolate mofetil and -6·8 (-17·2 to 3·6) with azathioprine (mean difference -3·3, 95% CI -7·7 to 1·2; p=0·15). 38 (81%) of 47 patients receiving mycophenolate mofetil and 18 (57%) of 31 receiving azathioprine had a CMR in MG-QOL15r (risk difference 24·0%; 95% CI -0·2 to 48·0; p=0·052). The clinical composite outcome was achieved in 22 (47·7%) of 47 patients who received mycophenolate mofetil and nine (28·1%) of 31 who received azathioprine (risk difference 19·6%, 95% CI -4·9 to 44·2; p=0·12). Descriptive analysis did not find a difference in the proportion of patients reaching a CMR in MG-QOL15r between the adequate dose and duration group and the lower dose or shorter duration group. Adverse events occurred in 11 (32%) of 34 patients who received azathioprine and nine (19%) of 48 who received mycophenolate mofetil. The most frequent adverse events were hepatotoxicity with azathioprine (five [15%] of 34) and gastrointestinal disturbances (seven [15%] of 48) with mycophenolate mofetil. There were no study-related deaths. INTERPRETATION: More than half of patients treated with azathioprine and mycophenolate mofetil felt their quality of life improved; no difference in clinical outcomes was noted between the two drugs. Adverse events associated with azathioprine were potentially more serious than those with mycophenolate mofetil, although mycophenolate mofetil is teratogenic. Lower than recommended doses of azathioprine might be effective, with reduced dose-dependent adverse events. More comparative effectiveness studies are required to inform treatment choices in myasthenia gravis. FUNDING: Patient-Centered Outcomes Research Institute, Myasthenia Gravis Foundation of America.
引用
- Narayanaswami P, Sanders DB, Thomas L, et al. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. Lancet Neurol. 2024. PMID: 38365379. doi:10.1016/S1474-4422(24)00028-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。